The North America dyslipidemia drugs market is supported by strong cardiovascular-care infrastructure, widespread cholesterol screening, and rising demand for advanced lipid-lowering therapies. The region's established pharmaceutical industry is also encouraging the development and adoption of targeted treatments, combination therapies, and newer non-statin approaches for patients who require...